Phase transformation in conformational polymorphs of nimesulide

Journal of Pharmaceutical Sciences

Volumn 100, Issue 6, 2011, Pages 2287-2299

  Sanphui, Palash ^a   Sarma, Bipul ^a   Nangia, Ashwini ^a  

^a UNIVERSITY OF HYDERABAD   (India)

Author keywords

Crystallization; Dissolution; FTIR; Phase transformation; Polymorphism; Raman spectroscopy; Solid state NMR; Solubility; Thermal analysis; X ray diffraction

Indexed keywords

NIMESULIDE; SULFONAMIDE;

ARTICLE; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG CONFORMATION; DRUG SOLUBILITY; GRINDING; HYDROGEN BOND; INFRARED RADIATION; MICROSCOPY; MOLECULAR INTERACTION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHASE TRANSITION; RAMAN SPECTROMETRY; SOLID STATE; THERMAL ANALYSIS; THREE DIMENSIONAL IMAGING; X RAY POWDER DIFFRACTION;

EID: 79954522910     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22464     Document Type: Article

References (50)

1. Dupont L, Pirrotte B, Masereel B, Delarge J, Geczy J. 1995. Nimesulide. J Acta Cryst C 51:507-509.
2. Moore GGI, Harrington JK. 1974. Substituted 2-phenoxy alkane sulfonamide. Patent Belgian801812, Patent US3840597.
3. Martino PD, Censi R, Barthelemy C, Gobetto R, Joiris E, Masic A, Odou P, Martelli S. 2007. Characterization and compaction behavior of nimesulide crystal forms. Int J Pharm 342:137-144.
4. Swingle KF, Moore GGI. 1984. Preclinical pharmaceutical studies with nimesulide. Drugs Exp Clin Res 10:587-589.
5. Villa G, Machhi F, Puttini PS. 2002. Use of nimesulide for the treatment of psoriasis and psoriatic arhtritis. Patent US0016369 A1.
6. Bergese P, Bontempi E, Colombo I, Gervasoni D, Depero LE. 2003. Microstructural investigation of nimesulide-crospovidone composites by X-ray diffraction and thermal analysis. Compos Sci Technol 63:1197-1201.
7. Bergese P, Alessandri I, Colombo I, Coceani N, Depero LE. 2005. Microstructre and morphology of nimesulide/crossprovidone nanocomposites by Raman and electronic microscopies. Compos Part A 36:443-448.
8. Singh A, Jain R. 2000. Parental water-miscible non-intensely colored injectable composition of non-steroidal anti-inflammatory drugs. Patent US6160019.
9. Piel G, Pirotte B, Delneuville I, Neven P, Llabres G, Delarge J, Delattre L. 1997. Study of the influence of both cyclodextrins and l-lysine on the aqueous solubility of nimesulide; isolation and characterization of nimesulide-l-lysine-cyclodextrin complexes. J Pharm Sci 86:475-480.
10. Davey RJ, Blagden N, Potts GD, Docherty R. 1997. Polymorphism in molecular crystals: Stabilization of a metastable form by conformational mimicry. J Am Chem Soc 119:1767-1772.
11. He X, Stowell JG, Morris KR, Pfeiffer RR, Li H, Stahly GP, Byrn SR. 2001. Stabilization of a metastable polymorph of 4-Methyl-2-nitroacetanilide by isomorphic additives. Cryst Growth Des 1:305-312.
12. Weissbuch I, Lahav M, Leiserowitz L. 2003. Toward stereochemical control, monitoring, and understanding of crystal nucleation. Cryst Growth Des 3:125-150.
13. Rubin-Preminger JM, Bernstein J. 2005. 3-Aminobenzenesulfonic acid: A disappearing polymorph. Cryst Growth Des 5:1343-1349.
14. Lǒpez-Mejías V, Kampf JW, Matzger AJ. 2009. Polymer-induced heteronucleation of tolfenamic acid: Structural investigation of a pentamorph. J Am Chem Soc 131:4554-4555.
15. Maruyama S, Ooshima H, Kato J. 1999. Crystal structures and solvent-mediated transformation of taltireline polymorphs. Chem Eng J 75:193-200.
16. Gu CH, Young Jr V, Grant DJW. 2001. Polymorph Screening: influence of solvents on the rate of solvent-mediated polymorphic transformation. J Pharm Sci 90: 1878-1890.
17. Ferrari ES, Davey RJ. 2004. Solution-mediated transformation of α to β L-glutamic acid: Rate enhancement due to secondary nucleation. Cryst Growth Des 4:1061-1068.
18. Trask AV, Jones W. 2005. Crystal engineering of organic co-crystals by the solid-state grinding approach. Top Curr Chem 254:41-70.
19. Babu NJ, Reddy LS, Aitipamula S, Nangia A. 2008. Polymorphs and polymorphic cocrystals of temozolomide. Chem Asian J 3:1122-1133.
20. Nangia A. 2008. Conformational polymorphism in organic crystals. Acc Chem Res 41:595-604.
21. Roy S, Banerjee R, Nangia A, Kruger GJ. 2006. Conformational, concomitant polymorphs of 4, 4-diphenyl-2, 5-cyclohexadienone: Conformation and lattice energy compensation in kinetic and thermodynamic forms. Chem Eur J 12:3777-3788.
22. 2 Materials Studio, and Gaussian 03, version 6.0, Programs to calcutate the lattice energy and conformational energy of polymorphs.
23. Gandhi RB, Bogardus JB, Bugay DE, Perrone RK, Kaplan MA. 2000. Pharmaceutical relationships of three solid state forms of stavudine. Int J Pharm 201:221-237.
24. Gu XJ, Jiang W. 1995. Characterization of polymorphic forms of fluconazole using fourier transform Raman spectroscopy. J Pharm Sci 84:1438-1442.
25. Tiwari M, Chawla G, Bansal AK. 2007. Quantification of olanzapine polymorphs using powder X-ray diffraction technique. J Pharm Biomed Anal 43:865-872.
26. Seaton CC, Treamayne M. 2002. Differential evolution: Crystal structure determination of a triclinic polymorph of adipamide from powder diffraction data. Chem Comm 880-881.
27. Burger A, Ramberger R. 1979. On the polymorphism of pharmaceuticals and other molecular crystals. Mikrochim Acta II:259-271.
28. Roy S, Bhatt PM, Nangia A, Kruger GJ. 2007. Stable polymorph of venlafaxine hydrochloride by solid-to-solid phase transition at high temperature. Cryst Growth Des 7:476-480.
29. Kimura K, Hirayama F, Uekama K. 1999. Characterization of tolbutamide polymorphs (Burger's forms II and IV) and polymorphic transition behavior. J Pharm Sci 88:385-391.
30. Sarma B, Roy S, Nangia A. 2006. Polymorphs of 1, 1-bis(4-hydroxyphenyl)cyclohexane and multiple Z' crystal structures by melt and sublimation crystallization. Chem Comm 4918-4920.
31. Tudor AM, Church SJ, Hendra PJ, Davies MC, Melia CD. 1993. The qualitative and quantitative analysis of chlorpropamide polymorphic mixtures by near-infrared Fourier transform Raman spectroscopy. Pharm Res 10:1772-1776.
32. Vrečer F, Vrbinc M, Meden A. 2003. Characterization of piroxicam crystal modifications. Int J Pharm 256:3-15.
33. Chesalov YA, Baltakhinov P, Drebushchak TN, Boldyreva EV, Chukanov NV, Drebushchak VA. 2008. FT-IR and FT-Raman spetra of five polymorphs of chlorpropamide, experimental study and ab intio calculations. J Mol Struc 891:75-86.
34. Reutzel-Edens SM, Bush JK, Magee PA, Stephenson GA, Byrn SR. 2003. Anhydrates and hydrates of olanzapine: crystallization, solid-state characterization, and structural relationships. Cryst Growth Des 3:897-907.
35. Kimura K, Hiryama F, Uekama K. 1999. Characterization of tolbutamide polymorphs (Burger's forms II and IV) and polymorphic transition behavior. J Pharm Sci 88:385-391.
36. Zencirci N, Gelbrich T, Apperley DC, Harris RK, Kahlenberg V, Grisser UJ. 2010. Structural features, phase relationships and transformation behavior of the polymorphs I-VI of phenobarbitol. Cryst Growth Des 10:302-313.
37. Tishmack PA, Bugay DE, Byrn SR. 2003. Solid-state nuclear magnetic resonance spectroscopy-Pharmaceutical applications. J Pharm Sci 92:441-474.
38. Laws DD, Bitter H-ML, Jerschow A. 2002. Solid-state NMR spectroscopic methods in chemistry. Angew Chem Int Ed 41:3096-3129.
39. Childs SL, Chyall LJ, Dunlap JT, Smolenskaya VN, Stahly BC, Stahly GP. 2004. Crystal engineering approach to forming cocrystals of amine hydrochlorides with organic acids. Molecular complexes of fluexetine hydrochloride with benzoic, succinic, and fumaric acids. J Am Chem Soc 126: 13335-13342.
40. Remenar JF, Morissette SL, Peterson ML, Moulton B, MacPhee JM, Guzmán HR, Almarsson Ö. 2003. Crystal engineering of novel cocrystals of a triazole drug with 1, 4-dicarboxylic Acids. J Am Chem Soc 125:8456-8457.
41. Pirrote B, Piel G, Neven P, Delneuville I, Geczy J. 1998. Water soluble nimesulide salt and its preparation, aqueous solution containing it, nimesulide-based combinations and their uses. Patent US5756546.
42. Pudipeddi M, Serajuddin ATM. 2005. Trends in solubility of polymorphs. J Pharm Sci 94:929-939.
43. Chemburkar SR, Bauer J, Deming K, Spiwek H, Patel K, Morris J, Henry R, Spanton S, Dziki W, Porter W, Quick J, Bauer P, Donaubauer J, Narayanan BA, Soldani M, Riley D, McFarland K. 2000. Dealing with the impact of ritonavir polymorphs on the late stages of bulk drug process development. Org Proc Res Dev 4:413-417.
44. Babu NJ, Cherukuvada S, Thakuria R. 2010. Conformational and synthon polymorphism in Furosemide (Lasix). Cryst Growth Des 10:1979-1989, and references cited therein
45. SAINT-Plus, version 6.45, Bruker AXS Inc., Program for X-ray data reduction and refinement, Madison, Wisconsin, USA, 2003.
46. Sheldrick GM, SHELXS-97 and SHELXL-97, Programs for the Solution and Refinement with anisotropic displacement parametrs for non hydrogen atoms of Crystal Structures, University of Göttingen, Göttingen, Germany, 1997.
47. SMART (Version 5.625) and SHELX-TL (Version 6.12), Bruker AXS Inc., Program to fix hydrogens through Fourier Map, Madison, Wisconsin, USA, 2000.
48. Barbour LJ. X-Seed, Graphical interface to SHELX-97 and POV-Ray, Program for better quality of crystallographic figures, University of Missouri-Columbia, Missouri, USA, 1999.
49. Spek AL. PLATON, A multipurpose crystallographic tool to check final cif file, Utrecht University, Utrecht, The Netherlands, 2002.
50. Kraus N, Nolze G. Powder Cell (version 2.3), Rietveld refinement was carried out with Powder Cell: Federal Institute for Materials Research and Testing, Berlin, Germany, 2000.